Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait

References

• Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. Adv Exp Med Biol. 2019;1165:3–15.
   PubMed Web of Science ®Google Scholar
• Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392(10159):2052–2090.
   PubMed Web of Science ®Google Scholar
• Farag YM, Kari JA, Singh AK. Chronic kidney disease in the Arab world: a call for action. Nephron Clin Pract. 2012;121(3-4):c120–c123.
   PubMedGoogle Scholar
• Shrestha N, Gautam S, Mishra SR, et al. Burden of chronic kidney disease in the general population and high-risk groups in South Asia: a systematic review and meta-analysis. PLoS One. 2021;16(10):e0258494.
   PubMed Web of Science ®Google Scholar
• GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204–1222.
   PubMed Web of Science ®Google Scholar
• The Global Health Observatory of WHO. Global health estimates: life expectancy and leading causes of death and disability. 2019 [accessed 2022 May]. Available from: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates
   Google Scholar
• Nugent RA, Fathima SF, Feigl AB, et al. The burden of chronic kidney disease on developing nations: a 21st century challenge in global health. Nephron Clin Pract. 2011;118(3):c269–c277.
   PubMedGoogle Scholar
• The World Bank. Data for Kuwait, high income. 2021 [accessed 2022 May]. Available from: https://data.worldbank.org/?locations=KW-XD
   Google Scholar
• AlSahow A, AlYousef A, AlHelal B, et al. Basic description of the dialysis population of Kuwait: the 2015 data. Saudi J Kidney Dis Transpl. 2016;27(6):1207–1210.
   PubMed Web of Science ®Google Scholar
• AlSahow A, AlHelal B, Alyousef A, et al. Renal data from the Arab world dialysis in Kuwait: 2013-2019. Saudi J Kidney Dis Transpl. 2020;31(4):826–830.
   PubMed Web of Science ®Google Scholar
• Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2005;67(6):2089–2100.
   PubMed Web of Science ®Google Scholar
• GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395(10225):709–733.
   PubMed Web of Science ®Google Scholar
• Elshahat S, Cockwell P, Maxwell AP, et al. The impact of chronic kidney disease on developed countries from a health economics perspective: a systematic scoping review. PLoS One. 2020;15(3):e0230512.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Dapagliflozin for treating chronic kidney disease. 2022 [accessed 2022 May]. Available from: https://www.nice.org.uk/guidance/ta775/resources/dapagliflozin-for-treating-chronic-kidney-disease-pdf-82611498049477
   Google Scholar
• Ferreira ES, Moreira TR, da Silva RG, et al. Survival and analysis of predictors of mortality in patients undergoing replacement renal therapy: a 20-year cohort. BMC Nephrol. 2020;21(1):502.
   PubMed Web of Science ®Google Scholar
• Medscape, what are the mortality rates associated with chronic kidney disease (CKD). 2021 [accessed 2022 May]. Available from: https://www.medscape.com/answers/238798-105284/what-are-the-mortality-rates-associated-with-chronic-kidney-disease-ckd
   Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305.
   PubMed Web of Science ®Google Scholar
• Heerspink H, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)–explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–250.
   PubMed Web of Science ®Google Scholar
• Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost–effectiveness of interventions: alternative approaches. Bull World Health Org. 2015;93(2):118–124.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices–overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Med Decis Making. 2012;32(5):667–677.
   PubMed Web of Science ®Google Scholar
• NICE, Single technology appraisal, Dapagliflozin for treating chronic kidney disease [ID3866]. 2021 [accessed 2022 May]. Available from: https://www.nice.org.uk/guidance/ta775/documents/committee-papers
   Google Scholar
• Sugrue DM, Ward T, Rai S, et al. Economic modelling of chronic kidney disease: a systematic literature review to inform conceptual model design. PharmacoEconomics. 2019;37(12):1451–1468.
   PubMed Web of Science ®Google Scholar
• McMurray J, Wheeler DC, Stefánsson BV, et al. Effects of dapagliflozin in patients with kidney disease, with and without heart failure. JACC Heart Fail. 2021;9(11):807–820.
   PubMed Web of Science ®Google Scholar
• Heerspink H, Cherney D, Postmus D, et al. A pre-specified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney Int. 2022;101(1):174–184.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
   PubMed Web of Science ®Google Scholar
• Jesky MD, Dutton M, Dasgupta I, et al. Health-related quality of life impacts mortality but not progression to end-stage renal disease in pre-dialysis chronic kidney disease: a prospective observational study. PLoS One. 2016;11(11):e0165675.
   PubMed Web of Science ®Google Scholar
• Kularatna S, Senanayake S, Gunawardena N, et al. Comparison of the EQ-5D 3L and the SF-6D (SF-36) contemporaneous utility scores in patients with chronic kidney disease in Sri Lanka: a cross-sectional survey. BMJ Open. 2019;9(2):e024854.
   PubMed Web of Science ®Google Scholar
• Li B, Cairns JA, Draper H, et al. Estimating health-state utility values in kidney transplant recipients and waiting-list patients using the EQ-5D-5L. Value Health. 2017;20(7):976–984.
   PubMed Web of Science ®Google Scholar
• Bertoldi EG, Rohde LE, Zimerman LI, et al. Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: the perspective of a middle-income country’s public health system. Int J Cardiol. 2013;163(3):309–315.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan VH. EQ-5D scores for diabetes-related comorbidities. Value Health. 2016;19(8):1002–1008.
   PubMed Web of Science ®Google Scholar
• World Bank. GDP per capita (current LCU) – Kuwait. 2020 [accessed 2022 Aug]. Available from: https://data.worldbank.org/indicator/NY.GDP.PCAP.CN?locations=KW
   Google Scholar
• World Bank Organization. PPP conversion factor, GDP (LCU per international $). 2021 [accessed 2022 May] Available from: https://data.worldbank.org/indicator/PA.NUS.PPP
   Google Scholar
• HAS. Committee meeting of dapagliflozin FORXIGA 10 mg film-coated tablets, Microsoft Word - FORXIGA_271021_SUMMARY_CT19370 (has-sante.fr). 2020 [accessed 2022 August]. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2021-03/forxiga_18112020_summary_ct18815.pdf
   Google Scholar
• Vareesangthip K, Deerochanawong C, Thongsuk D, et al. Cost-utility analysis of dapagliflozin as an add-on to standard of care for patients with chronic kidney disease in Thailand. Adv Ther. 2022;39(3):1279–1292.
   PubMed Web of Science ®Google Scholar
• McEwan P, Darlington O, Wheeler D, et al. POS-335 cost-effectiveness of dapagliflozin as a treatment for chronic kidney disease: a health-economic analysis of DAPA-CKD. Clin J Am Soc Nephrol. 2022;17(12):1730–1741.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Wheeler DC, Stefánsson BV, et al. Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease. Circulation. 2021;143(5):438–448.
   PubMed Web of Science ®Google Scholar
• Kuwait, Life expectancy, Kidney disease in Kuwait. 2020 [accessed 2022 Aug]. Available from: worldlifeexpectancy.com
   Google Scholar
• Chertow GM, Vart P, Jongs N, et al. Effects of dapagliflozin in stage 4 chronic kidney disease. J Am Soc Nephrol. 2021;32(9):2352–2361.
   PubMed Web of Science ®Google Scholar
• Huang Y, Lu W, Lu H. The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy. Diabetol Metab Syndr. 2022;14(1):47.
   PubMed Web of Science ®Google Scholar
• Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis [published correction appears in Lancet Diabetes Endocrinol. 2019;7(12):e23]. Lancet Diabetes Endocrinol. 2019;7(11):845–854.
   PubMed Web of Science ®Google Scholar
• Wheeler DC, Jongs N, Stefansson BV, et al. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Nephrol Dial Transplant. 2022;37(9):1647–1656.
   PubMed Web of Science ®Google Scholar
• AlSahow A, AlYousef A. Global dialysis perspective: Kuwait. Kidney360. 2021;2(6):1015–1020.
   PubMedGoogle Scholar
• Heerspink HJL, Sjöström CD, Jongs N, et al. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. Eur Heart J. 2021;42(13):1216–1227.
   PubMed Web of Science ®Google Scholar
• Albatineh AN, Ibrahimou B. Factors associated with quality-of-life among Kuwaiti patients on maintenance hemodialysis. Psychol Health Med. 2019;24(8):1005–1014.
   PubMed Web of Science ®Google Scholar
• Tisdale RL, Cusick MM, Aluri KZ, et al. Cost-Effectiveness of dapagliflozin for non-diabetic chronic kidney disease. J Gen Intern Med. 2022;37(13):3380–3387.
   PubMed Web of Science ®Google Scholar